carbidopa, levodopa drug combination has been researched along with Abnormal Movements in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (16.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 8 (66.67) | 24.3611 |
2020's | 2 (16.67) | 2.80 |
Authors | Studies |
---|---|
D'Souza, R; Fisher, S; Hauser, RA; Zeitlin, L | 1 |
Altiparmak, E; Erdoğan Küçükdağli, F; Köseoğlu, HT; Öztürk, Ö; Saltoğlu, T; Sücüllü Karadağ, Y | 1 |
Dinh, P | 1 |
Antonini, A; Bergmann, L; Chaudhuri, KR; Poewe, W | 1 |
Gupta, S; Hsu, A; Mao, Z; Modi, NB | 1 |
Ossig, C; Reichmann, H | 1 |
Jog, MS; Kumar, N; Rizek, P | 1 |
Avolio, C; De Francesco, V; Lalla, A; Martino, T; Melchionda, D; Specchio, LM; Tonti, P | 1 |
Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
Eggert, K; Eichhorn, T; Oertel, WH; Ries, V; Selzer, R | 1 |
Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM | 1 |
Scheife, RT | 1 |
2 review(s) available for carbidopa, levodopa drug combination and Abnormal Movements
Article | Year |
---|---|
Treatment of Parkinson's disease in the advanced stage.
Topics: Antiparkinson Agents; Carbidopa; Dopamine Agonists; Drug Combinations; Dyskinesias; Humans; Levodopa; Parkinson Disease | 2013 |
An update on the diagnosis and treatment of Parkinson disease.
Topics: Age of Onset; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Dyskinesias; Humans; Levodopa; Life Expectancy; Parkinson Disease; Practice Guidelines as Topic; Risk Assessment | 2016 |
4 trial(s) available for carbidopa, levodopa drug combination and Abnormal Movements
Article | Year |
---|---|
A Transitional Probability Model for Parkinson's Disease Motor States With Applications to Missing Data.
Topics: Aged; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Double-Blind Method; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Models, Statistical; Movement; Parkinson Disease | 2019 |
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Models, Biological; Parkinson Disease | 2013 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Topics: Aged; Ambulatory Care Facilities; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Feasibility Studies; Female; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Severity of Illness Index; Time Factors; Tolcapone; Treatment Outcome | 2010 |
6 other study(ies) available for carbidopa, levodopa drug combination and Abnormal Movements
Article | Year |
---|---|
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Capsules; Carbidopa; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 2020 |
Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients
Topics: Abdomen, Acute; Aged; Carbidopa; Catheterization; Deglutition Disorders; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Dysarthria; Dyskinesias; Endoscopy; Female; Gait; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Quality of Life; Severity of Illness Index; Treatment Outcome; Turkey | 2021 |
Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.
Topics: Aged; Carbidopa; Dopamine Agents; Drug Combinations; Dyskinesias; Female; Gels; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Registries | 2019 |
Weight loss and decubitus duodenal ulcer in Parkinson's disease treated with levodopa-carbidopa intestinal gel infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Duodenal Ulcer; Duodenum; Dyskinesias; Endoscopes, Gastrointestinal; Humans; Levodopa; Male; Parkinson Disease; Tomography, X-Ray Computed; Weight Loss | 2016 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders | 1999 |
Successful orchestration of antiparkinsonian pharmacotherapy.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Comorbidity; Disease Progression; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacists | 1999 |